Innovation Report

Stephan Emmerth

Stephan Emmerth

PhD | Senior Project Manager Biotech, Business Development Senior Manager BaseLaunch


Tel. +41 61 295 50 17

stephan.notexisting@nodomain.comemmerth@baselarea.notexisting@nodomain.comswiss
report Life Sciences
Logo Evolva (Img: Evolva)

Logo Evolva (Img: Evolva)

01.06.2017

Evolva in negotiations with US government over funding

An Evolva ingredient can likely be used in the battle against the Zika virus. The Basel-based company is now in negotiations with the US government over funding its further development.

Evolva has confirmed a media report that it is in negotiations with the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development and EPA registration of its nootkatone product, which is derived from citrus fruits.

Evolva has been collaborating for some time with US institutions to research the efficacy of nootkatone. Together with the Center for Disease Control and Prevention (CDC), Evolva investigated the efficacy of nootkatone against ticks, which are responsible for spreading Lyme disease.

In February 2016, this research was expanded to mosquitos, which can transmit the Zika virus. Last summer, the National Institutes of Health (NIH) announced that they will sponsor studies on this subject with the US National Institute of Allergy and Infectious Diseases (NIAID). The results available to date will be taken into account.

Nootkatone can be used against mosquitos that contribute to the spread of Zika, dengue and other viruses. It is also being tested against other biting insects such as head lice and bed bugs. Evolva develops ingredients for health, wellness and nutrition.

Categories

Life Sciences
Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok